Patent cliffs & loss of exclusivity
Arrowhead Pharmaceuticals is a Pasadena, California-based biotechnology and pharmaceuticals company developing RNA interference medicines that silence disease-causing genes. It uses its proprietary Targeted RNAi Molecule (TRiM) platform for drug discovery and tissue-targeted delivery. Its commercial product REDEMPLO (plozasiran) is approved in the United States for adults with familial chylomicronemia syndrome, while its pipeline includes investigational cardiometabolic, pulmonary and other RNAi therapies.
| AngelList URL | https://angel.co/company/arrowhead-pharmaceuticals |
|---|---|
| Legal Name | Arrowhead Pharmaceuticals, Inc. |
| Company Operating Status | Active |
| Crunchbase URL | https://www.crunchbase.com/organization/arrowhead-research#section-overview |
| Email format | {f}{last} |
| Facebook URL | https://www.facebook.com/pages/Arrowhead-Research/101026823293246 |
| Fax Number | 626-304-3401 |
| Full Address | 177 East Colorado Boulevard, Suite 700 Pasadena, CA 91105 |
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.